No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
Market latest
FTSE 100 | FTSE 250 | Paris CAC 40 | Dow Jones | NASDAQ
9548.87 |
65.29 (0.69%)
22041.83 |
39.03 (0.18%)
46623.62 |
20.64 (0.04%)
22985.35 |
196.99 (0.86%)
8060.13 |
85.28 (1.07%)
NaN |
0.00 (0.00%)
Prices delayed by at least 15 minutes
(Sharecast News) - Stocks in London were being called to start the session with a slight downward bias.
That was despite an overnight surge in Japanese stocks on news of a surprise victory by a pro-stimulus lawmaker, Sanae Takaichi, in a leadership vote within Japan's ruling party.
Weighing on investor sentiment, France's new prime minister, Sebastien Lecornu, opted to keep all the members of his cabinet.
That was prompting concern that the current government would fail to pass a new budget, possibly risking fresh elections.
As of 0821 BST, FTSE 100 futures were off by 3.50 points to 9,529.0.
In parallel, cable was falling 0.32% to 1.3437, Brent crude oil futures were adding 0.68% to $65.21 a barrel on the ICE and COMEX gold futures were a full percentage point higher to $3,952.10.
Helping to lift the latter, on Sunday OPEC+ countries agreed to boost their combined output by another 137,000 barrels a day.
That was less than expected by some economists.
In Japan, the Nikkei-225 was advancing by 4.93% to 48,027.36.
Ten-year French government bond yields were trading six basis points higher at 3.569%.
US equity futures were moving modestly higher.
On the economic calendar for Monday, at 0930 BST consultancy S&P Global would release its construction sector Purchasing Managers' Index for the month of September.
Ferrexpo boosts output
Mining giant Ferrexpo reported a modest rise in third-quarter output on Monday, as strong Chinese demand for high-grade concentrate helped offset reduced pellet production amid liquidity constraints. Total commercial production rose 3.3% quarter-on-quarter to 1.51m tonnes, though it remained 29% below Q1 levels.
AstraZeneca announced that its Datroway therapy against breast cancer had achieved positive high-level results in a Phase III trial both in terms of overall survival and progression-free survival.